Citations

Clear

6273 citation(s) found for "To, Andrew".

An interim analysis of the influence of eating disorder risk, body dissatisfaction, physical activity, and diet on bone mineral density in college-aged females
Allen, Leah E. , Le, Christine , Horlock, Conor F., Jones, Margaret T. , Fields, Jennifer B. , Le, Christy V., Jagim, Andrew R.

Mayo Clinic

Journal of the International Society of Sports Nutrition | November 4, 2025 | Volume: 22 | Issue: sup2 | Pages: No page available

10.1080/15502783.2025.2550169 Get It

Visualizing Real‐World Pain Treatment Pathways in Chronic Disease: A Sequence‐Based Analysis of Polypharmacy in Systemic Lupus Erythematosus
Le, Nathan , Walker, Andrew , Park, Tricia , Chaichian, Yashaar , Weisman, Michael H., Irani, Anushka, Falasinnu, Titilola , Irani, Anushka , Walker, Andrew , Chaichian, Yashaar , Falasinnu, Titilola , Irani, Anushka , Kenney, Martha O , Bozkurt, Selen

Mayo Clinic

ACR Open Rheumatology | November 4, 2025 | Volume: 7 | Issue: 11 | Pages: No page available

10.1002/acr2.70116 | PMID 41183802 Get It

Objective To examine real‐world patterns in pain management among adults with systemic lupus erythematosus (SLE), we focused on the sequencing of pain modalities, polypharmacy, and demographic variation. Methods We conducted a retrospective analysis of electronic health records from adults with SLE treated at a single academic medical center between 2005 and 2024. We included patients who received at least one pain‐related therapy, including glucocorticoids, opioids, nonsteroidal anti‐inflammatory drugs (NSAIDs), antidepressants, anticonvulsants, muscle relaxants, and nonpharmacologic interventions. We used sequence analysis and Sankey diagrams to map treatment trajectories and compared patterns across two periods: 2005 to 2014 and 2015 to 2024. Polypharmacy was defined as receiving five or more pain‐related prescriptions within 12 months. We examined trends by age, sex, and race or ethnicity. Results Among 769 patients, initiation of glucocorticoids and opioids declined over time (58%–51% and 28%–22%, respectively), whereas NSAID use increased (19%–29%). The median number of pain prescriptions decreased, and polypharmacy prevalence dropped from 53% to 45%. In recent years, younger adults and men received more prescriptions, with 69% of men receiving five or more compared with 43% of women. Racial disparities narrowed overall in recent years but persisted in sensitivity analyses excluding glucocorticoids. Conclusion Pain management in SLE is shifting away from high‐risk therapies; however, prescribing intensity remains high and varies by demographic group. Visualizations serve as a complementary lens to traditional prescription counts, allowing representation of polypharmacy not only by volume but also by the diversity and sequencing of therapeutic classes over time.
2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus
Sammaritano, Lisa R. , Askanase, Anca , Bermas, Bonnie L. , Dall’Era, Maria , Duarte‐García, Alí , Hiraki, Linda T. , Aranow, Cynthia , Barnado, April , Broder, Anna , Chowdhary, Vaidehi , Hersh, Aimee O. , Jules, Marimee, Kalunian, Kenneth , Smith, Benjamin J. , Smith, Natalie, Thomas, Asha , Timlin, Homa , Cunha, Joanne S., DeQuattro, Kimberly , Gomes, Laís Lopes Almeida , Iyer, Priyanka , Johannemann, Andrew, Jorge, April , Kasturi, S.Psi. Taufik , Khawandi, Jana , Legge, Alexandra , Liang, Kimberly P. , Lockwood, Megan M. , Sánchez-Rodríguez, Alain , Turgunbaev, Marat, Williams, Jessica N. , Turner, Amy S. , Aranow, Cynthia , Barnado, April , Brunner, Hermine I , Chong, Benjamin F , Hersh, Aimee O , Rubinstein, Tamar B , Smith, Benjamin J , Wallace, Daniel J , Bartels, Christie M , DeQuattro, Kimberly , Figueroa-Parra, Gabriel , Garg, Shivani , Gomes, Lais Lopes Almeida , Cuéllar-Gutiérrez, María C, Jorge, April , Kasturi, Shanthini , Kawtharany, Hassan , Liang, Kimberly P , Lockwood, Megan M , Sanchez-Rodriguez, Alain , Williams, Jessica N , Turner, Amy S , Duarte-García, Alí , Sammaritano, Lisa R , Askanase, Anca , Bermas, Bonnie , Son, Mary Beth F. , Werth, Victoria P. , Chong, Benjamin F. , Izmirly, Peter , Kamen, Diane L. , Thomas, Asha, Azzam, Muayad , Bartels, Christie M. , Fava, Andrea , Figueroa‐Parra, Gabriel , Garg, Shivani , Cuéllar‐Gutiérrez, María C. , Kawtharany, Hassan , Mustafa, Reem A

Mayo Clinic

Arthritis Care & Research | November 3, 2025 | Volume: 78 | Issue: 7 | Pages: 815-839

10.1002/acr.25690 | PMID 41182321 Get It

Objective To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.
Predictive modeling of long-term improvement in occlusion outcomes following Woven EndoBridge treatment of cerebral aneurysms: A machine learning approach
Karandish, Alireza , Essibayi, Muhammed Amir , Jabal, Mohamed Sobhi , Salim, Hamza , Musmar, Basel , Adeeb, Nimer , Dibas, Mahmoud , Li, Yan-Lin , Grist, James T. , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Naamani, Kareem El, Möhlenbruch, Markus, Kral, Michael , Salem, Mohamed M , Foreman, Paul M. , Shaikh, Hamza , Župančić, Vedran , Ayberk, Gıyas , Rabinov, James D. , Maingard, Julian , Michelozzi, Caterina , Starke, Robert M., Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Pukenas, Bryan , Burkhardt, Jan‐Karl , Slawski, Diana , Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Raz, Eytan , Asadi, Hamed , Siddiqui, Adnan H. , Haranhalli, Neil , Ducruet, Andrew F. , Albuquerque, Felipe C , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter , Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Patel, Aman B. , Fuschi, Maurizio , Altschul, David , Investigators, for the WorldWideWEB, Salim, Hamza , Li, Yan-Lin , Algin, Oktay , Ghozy, Sherief , Guenego, Adrien , Shotar, Eimad , Lylyk, Ivan , Foreman, Paul M , Župančić, Vedran , Hafeez, Muhammad U , Ayberk, Giyas , Schirmer, Clemens M , Hassan, Ameer E , Nguyen, Anh , Jones, Jesse , Ulfert, Christian , Tawk, Rabih, Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Levy, Elad I , Regenhardt, Robert W , Tjoumakaris, Stavropoula , Cuellar-Saenz, Hugo H , Jabbour, Pascal , Limbucci, Nicola , Altschul, David J , Dmytriw, Adam A , Dibas, Mahmoud , Pero, Guglielmo , Kalousek, Vladimir , Musmar, Basel , Essibayi, Muhammed Amir , Lay, Sovann V , Simonato, Davide , Zaccagna, Fulvio , Ghozy, Sherief , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El, Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Kazancı, Atilla , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Pulli, Benjamin , Panni, Pietro , Puri, Ajit S , Griessenauer, Christoph J. , Levy, Elad I. , Cuellar, Hugo , Jabbour, Pascal , Limbucci, Nicola , Dmytriw, Adam A. , Investigators, for the WorldWideWEB

Mayo Clinic

Interventional Neuroradiology | November 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199251391915 | PMID 41182964 Get It

Background The Woven EndoBridge (WEB) device represents an innovative solution for cerebral aneurysm occlusion, particularly for challenging wide-neck bifurcation aneurysms. However, factors affecting sustained occlusion remain poorly understood. We utilized machine learning to attempt to identify predictors of favorable long-term outcomes following WEB treatment. Methods In this multicenter retrospective study, we collected patient demographics, aneurysm characteristics, procedural details, and clinical outcomes. The primary endpoint was improvement in occlusion status, defined as maintained Raymond-Roy Occlusion Classification (RROC) grade 1, or improvement from grade 2 to 1, or from grade 3 to either 2 or 1 on final angiographic follow up. The dataset was split into training (75%) and validation (25%) sets. The CatBoost algorithm was selected based on performance metrics, with Shapley Additive exPlanations (SHAP) values calculated to determine feature importance. Furthermore, a multivariable binomial logistic regression model was performed to validate machine learning findings. Results Among 720 aneurysms from 36 hospitals, 84% showed improvement in occlusion at follow up. Both machine learning and multivariable logistic regression identified aneurysm height as the most consistent correlate of nonimprovement (odds ratio (OR) 0.90 per mm, p = 0.022). In the CatBoost model, the highest-ranking features by SHAP included aneurysm height, patient age, treatment acuity, ACom location, WEB-SLS device, bifurcation anatomy, aneurysm multiplicity, baseline modified Rankin Scale, access route, and partial thrombosis. Conclusions Machine-learning and regression analyses identified consistent predictors of occlusion improvement after WEB treatment, with aneurysm height most strongly linked to nonimprovement. These insights may guide patient selection and follow up. Findings require cautious interpretation and external validation in larger cohorts.
Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Lazare, Seka , Gu, Zhuosheng , Earland, Noah , Harmon, M. , Pacula, Maciej , Rivera, Megan , Tellis, Ashley , Whitfield, Damion , Benson, Adam , Gerndt, Sophie P. , Khalil, Lucien , Xu, Zhongping , Wahle, Benjamin M. , Zandberg, Dan P. , Spector, Matthew E. , Seethala, Raja R. , Smith, Joshua D. , Greer, Amy , Verner, Ellen L. , Georgiadis, Andrew , Ramkissoon, Shakti , Jensen, Taylor J. , Francis, Marra S. , Winckler, Wendy , Chaudhuri, Aadel A. , Harmon, Michael A , Gerndt, Sophie , Harris, Peter K , Khalil, Lucien , Ramirez, Ricardo , Xu, Zhongping , Wahle, Benjamin , Puram, Sid , Adkins, Douglas , Thorstad, Wade , Zandberg, Daniel , Chernock, Rebecca , Skinner, Heath Devin , Spector, Matthew E , Seethala, Raja , Ferris, Robert L , Smith, Joshua D , Greer, Amy E , Verner, Ellen L , Georgiadis, Andrew , Sausen, Mark , Ramkissoon, Shakti H , Jensen, Taylor J , Francis, Marra S , Winckler, Wendy , Chaudhuri, Aadel A , Zevallos, Jose , Rivera, Megan , Adkins, Douglas R. , Ferris, Robert L. , Zevallos, Jose P.

Mayo Clinic

Clinical Cancer Research | November 3, 2025 | Volume: 32 | Issue: 1 | Pages: 135-147

10.1158/1078-0432.ccr-25-1221 | PMID 41182409 Get It

Abstract Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.
Abstract 4365545: Outcomes of Heart Failure in Muscular Dystrophies in Adults: A Nationwide Analysis in the United States
Jabbar, Ali Bin Abdul, Al-Salahat, Ali, Dilsaver, Danielle B., Ismayl, Mahmoud, Goldsweig, Andrew, Aboeata, Ahmed, Jabbar, Ali Bin Abdul, Al-Salahat, Ali, Dilsaver, Danielle B., Ismayl, Mahmoud, Goldsweig, Andrew, Aboeata, Ahmed

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4365545 Get It

Background: Muscular dystrophies (MDs) may cause heart failure (HF), but outcomes specific to MD-related HF are not well characterized. Research Question: Do the outcomes of HF hospitalizations differ between patients with underlying MDs (MD-HF) vs. patients without MDs (non-MD-HF) in the United States? Methods: Discharge data from HF hospitalizations were abstracted from the Nationwide Readmissions Database (2016-2022) and stratified by the presence or absence of MD (MD-HF vs. non-MD-HF). Logistic regression and lognormal models were estimated to assess differences in inpatient mortality, length of stay (LOS), total costs, complications, and 30-day and 90-day all-cause readmissions. Propensity-score matching (PSM) was used to control baseline differences between the MD-HF and non-MD-HF cohorts. Odds ratios (OR) with associated 95% Confidence intervals (CI) and p-values were reported. Analyses were conducted via SAS v. 9.4, with statistical significance indicated by two-tailed p<.05. Results: 8,466,806 HF hospitalizations were included in the analysis, of which 3688 (0.04%) involved patients with MD. MD-HF hospitalizations involved younger patients (mean age 55.3 vs. 71.3 years, p<0.001) with higher rates of HF with reduced ejection fraction (HFrEF) compared to non-MD-HF hospitalizations (48.1% vs. 34.9%, p<0.001). Compared to non-MD-HF hospitalizations (2.01%), MD-HF hospitalizations (5.82%) were associated with significantly higher odds of inpatient mortality (OR 3.01, 95% CI: 2.03, 4.45); higher complications rate (OR 2.11, 95% CI, 1.77, 2.52) including cardiogenic shock (OR 2.61, 95% CI, 1.90, 3.59), cardiac arrest (OR 2.27, 95% CI, 1.17, 4.41), use of mechanical ventilation (OR 2.23, 95% CI, 1.82, 2.73); higher palliative care consultation (OR 4.52, 95% CI, 3.21, 6.36); as well as more extended hospital LOS (OR 1.18, 95% CI, 1.09, 1.29), higher total costs (OR 1.32, 95% CI, 1.24, 1.41), and higher odds of discharge to rehab facility (OR 2.46, 95% CI, 1.99, 3.03) and home healthcare (OR 1.85, 95% CI, 1.55, 2.21) (all p<0.001). MD was not associated with a significant difference in 30-day (OR 0.94, 95% CI, 0.78, 1.12) and 90-day (OR 0.98, 95% CI, 0.82, 1.17) all-cause readmission rates. Conclusion: MD-HF hospitalizations were associated with higher inpatient mortality, complication rates, resource utilization, discharge to rehab facility and home healthcare, and no difference in readmission rates compared to non-MD-HF hospitalizations.
Abstract 4371085: Seasonal Patterns and Geographic Disparities in United States Cardiovascular Mortality between 1999-2020
Raju, Arvind kumar Venkataramana, Gajjar, Aryan , Joshi, Amir, Chirumamilla, Sri Sai Kaumudi, Pathiyil, Mythili Menon , Goldsweig, Andrew M.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4371085 Get It

Introduction: Seasonal, geographic, and socioeconomic factors all influence cardiovascular (CV) mortality. Long-term seasonal trends across United States regions remain insufficiently characterized. Research Question: We evaluated longitudinal trends in CV mortality across seasons in the U.S., stratified by geographic region and degree of urbanisation, from 1999 through 2020. Methods: Data on CV mortality (ICD-10: I00-I99) were extracted from the CDC WONDER database and stratified by season (Winter, Spring, Summer, Fall), U.S. Census region (Northeast, Midwest, South, West), and degree of urbanisation (6-level National Center for Health Statistics classification). Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was used to estimate annual percent change (APC) and average annual percent change (AAPC) with 95% confidence intervals. Results: From 1999 to 2020, 18.8 million CV deaths were recorded (Table 1). Winter accounted for the highest mortality burden across all regions and urban settings but also showed the greatest improvement of the the 20-year study period, with AAPC reductions most pronounced in the Northeast (–2.83%) and Large Central Metro areas (–2.79%; p < 0.000001 for all trends; Figure 1). Summer and Fall, while associated with fewer deaths, showed slower progress, particularly in the Midwest (Fall AAPC: –1.81%; Summer: –1.77%) and rural areas (NonMetro Fall AAPC: –1.56%). Notably, Midwest Fall mortality demonstrated a statistically significant reversal, with an APC increase of +3.87% from 2018 to 2020 (p = 0.02)(Figure 1). Conclusion: CV mortality in the U.S. follows a distinct and evolving seasonal pattern. Although winter remains the deadliest season, it has seen the most substantial mortality reductions, likely tied to improved awareness, continuity of care, and cold-weather adaptations. However, slower progress during summer and fall, particularly in the Midwest and rural areas, reveals growing seasonal and geographic disparities. Most notably, the recent and statistically significant rise in Midwest fall mortality signals an urgent concern. This reversal may reflect emerging climate stressors such as prolonged heat, air pollution, and environmental volatility during transitional months compounded by reduced healthcare access or changing behavioral risk factors. These findings call for year-round, seasonally tailored public health strategies especially for underserved and climate-vulnerable populations.
Abstract 4370594: Associations Between Chronic Kidney Disease and Inflammatory Biomarkers in the Genetic Epidemiology Network of Arteriopathy Cohort
Javaid, Syed Sarmad , Lirette, Seth T. , Khan, Laibah, Windham, B. Gwen , Butler, Kenneth R. , Tio, Maria Clarissa , Butler, Javed , Hall, Michael E. , Butler, Kenneth R , Lirette, Seth , Khan, Laibah Arshad , Kullo, Iftikhar J. , Rule, Andrew D.

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4370594 Get It

Background: Chronic kidney disease (CKD) has been linked to elevated inflammatory biomarkers, yet few studies have evaluated these associations using iothalamate-based measures of kidney function, highlighting the need for further research. Research question: Is CKD associated with elevated inflammatory markers when defined by measured glomerular filtration rate (mGFR) and urinary albumin-to-creatinine ratio (UACR)? Methods: Participants from the Genetic Epidemiology Network of Arteriopathy (GENOA) cohort were included if they had data available for at least one inflammatory marker at visit 2. 17 inflammatory markers were assessed, including C-reactive protein (CRP), interleukin-6 (IL-6), IL-18, tumor necrosis factor receptors 1 and 2 (TNFR1, TNFR2), serum amyloid A, intercellular and vascular adhesion molecules (ICAM, VCAM), E-selectin, P-selectin, monocyte chemoattractant protein (MCP), myeloperoxidase (MPO), receptor for advanced glycation end products (RAGE), matrix metalloproteinases 2 and 9 (MMP-2, MMP-9), and tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1, TIMP-2). Kindey function was assessed using the urinary clearance of iothalamate. CKD was defined as mGFR < 60 mL/min/1.73 m 2 or UACR ≥ 30 mg/g. To further assess whether associations persisted without albuminuria, we also defined CKD solely by mGFR < 60 mL/min/1.73 m 2 . Generalized estimating equations (GEE) were used to assess associations between CKD status and inflammatory markers, accounting for familial clustering. Exponentiated beta coefficients from GEE models were used to present geometric mean (GM) ratios of each biomarker by CKD status, adjusted for demographics, lifestyle factors, cardiovascular risk factors, and medication use. Results: Among 1,010 participants (mean age 61 ± 10 years; 67% women; 48% Black adults), 207 were classified as having CKD. After adjusting for potential confounders, individuals with CKD had significantly higher levels of hsCRP, VCAM, TNFR1, and TNFR2 compared to those without CKD (GM ratios > 1; p < 0.05), while the remaining inflammatory markers showed no significant differences ( Figure 1 ). Importantly, these elevations remained significant when CKD was defined by mGFR alone ( Figure 2 ). Conclusion: Our findings suggest that CKD, defined by mGFR, is associated with specific inflammatory biomarkers, underscoring the need for mechanistic studies to investigate these associations.
Abstract 4363387: Porcine Model of Biventricular Pressure-Volume Loop Assessment during Impella 5.5 Support
Rahme, Serena, Witt, Tyra A. , Nagel, Mary, Tiffany, Sarrafian, Tollefsrud, Katrina, Yalamuri, Suraj , Rosenbaum, Andrew , Inglis, Sara S. , Nagel, Mary, Tiffany, Sarrafian, Behfar, Atta

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4363387 Get It

Introduction: The Impella 5.5 is frequently employed to provide temporary mechanical circulatory support as bridge to recovery or durable therapy. Optimization of device management relies on understanding ventricular pressure-volume (PV) relationships. Aim: The aim of this study was to evaluate the biventricular (BiV) relationship with PV loop assessment during Impella 5.5 support in non-myopathic ventricles. Methods: Six domestic Yorkshire Pigs were used for this study. The Impella 5.5 (J&J MedTech, NJ) was inserted percutaneously under ultrasound and fluoroscopic guidance through either the carotid artery or aortic arch, using a 26Fr DrySeal Sheath (Gore, AZ). BiV PV loop conductance catheters (Sigma-M, CD Leycom, Hengelo, The Netherlands) were inserted via femoral venous access. The LV PV loop catheter is positioned via transeptal puncture and with intracardiac echocardiogram guidance. BiV PV loops are generated for each level of Impella 5.5 support. Results: With increasing levels of Impella 5.5 support, left ventricular (LV) PV loops shifted increasingly to the left and right ventricular (RV) loops to the right. Accordingly, LV end-diastolic volume (EDV) decreased (110±4 ml to 90±8 ml; p<0.001) and RV EDV increased (121±7 ml to 147±13 ml; p<0.001), from baseline to P9. Native LV systolic function decreased with increasing Impella 5.5 support, as demonstrated by a reduction in stroke volume (SV) (56±5 ml to 49±5 ml; p<0.001), cardiac output (CO) (3.4±0.8 ml/min to 2.0±0.3 ml/min; p<0.001), ejection fraction (EF) (51±4% to 44±6%; p<0.001), stroke work (SW) (4483±1023 ml*mmHg to 2383±719 ml*mmHg; p<0.001), and LV peak positive dP/dt (825 ± 184 mmHg/s to 523 ± 99 mmHg/s; p<0.001). Conversely, the native RV experienced preload-mediated increase in SV (65±7 ml to 86±20 ml; p<0.001), CO (3.7±0.8 ml/min to 4.3±0.9 ml/min; p<0.001), EF (53±4% to 58±11%; p<0.001), SW (918±143 ml*mmHg to 1529±365 ml*mmHg; p<0.001), and RV dP/dt (164±16 mmHg/s to 228±29 mmHg/s, p<0.001). Load independent contractility was assessed in the LV (1.64±0.33 mmHg/ml to 1.71±0.41 mmHg/ml; p=0.2) and RV (0.25±0.04 mmHg/ml to 0.29±0.05 mmHg/ml; p<0.001). Conclusions: This study highlights ventricular interdependence with Impella 5.5 support with opposing BiV trends. In a healthy heart, the RV can adequately compensate for increased preload offered by the device.